BioBlast w/e 23 Oct 23

Celltrion announced that the FDA has approved its subcutaneous formulation of Zymfentra® (infliximab -dyyb), biosimilar to Janssen’s Remicade®, as…

Related Keywords

India ,Canada ,France ,Japan ,Netherlands ,South Korea ,Australia ,China ,Chinese ,South Korean ,Canadian ,Astrazeneca Alexion Soliris ,Astrazeneca Daiichi ,Abbvie Humira ,Samsung Bioepis ,Celltrion Adalimumab Biosimilar ,Daiichi Sankyo Enhertu ,Samsung Bioepi Epysqli ,Samsung Biologics ,Merck Keytruda ,Samsung Bioepi Eticovo ,Amgen Enbrel ,Daiichi Sankyo ,Novarti Erelzi ,Celltrion Zymfentra ,Janssen Remicade ,Europe The European Commission ,Authority Required ,European Commission ,Samsung ,Authority Script ,Chinese National Medical Products Administration ,Services Australia ,Health Canada ,Health Canada Approves Abbvie Rinvoq ,Astrazeneca ,Approval Alert ,First Approved ,Authority Script Changes ,Promote Uptake ,Pharmaceutical Benefits Scheme ,Sanofi Receive ,Complete Response Letter ,Samsung Biologics Receives Form ,South Korean Manufacturing ,Food Drug ,Samsung Bioepis Launches Epysqli ,Korea Heraldreported ,Bioepi Epysqli ,Daiichi Sankyo Ink ,Global Commercialisation Deal ,Three Deruxtecan Antibody Drug ,New Indication Alert ,Health Canada Approves Abbvie ,Severe Crohn ,Active Non Radiographic Axial ,Carepartners Pharmacy ,Exclusively Supply Celltrion ,Adalimumab Biosimilar ,Celltrion United States ,Law ,Lawyers ,Legal ,Aw Firms ,Aw Updates ,Egal Updates ,Egal Developments ,Aw Developments ,Egal Newsletters ,Egal Current Awareness ,Deals ,Egal Advisers ,Egal Advisors ,Egal Directory ,Ealthcare Amp Life Sciences ,